|
The cyclin-dependent kinase inhibitors
These kinase inhibitors can work across various types of cancer, but often only extend life by around three to six months. However, researchers believe they can unlock the true potential of these drugs by changing the way they are used, after uncovering a hidden way that they work. Those researchers had planned to conduct clinical trials using kinase inhibitors at higher doses, but with rest periods to take advantage of the new mechanism, and believe the new method has the potential to keep cancers at bay for much longer.
Some private laboratory oncologists have found that high-dose kinase inhibitors can be effective for central nervous system (CNS) disease, so long as resistance has not developed. It may have something to do with entry into the cell; efflux out of the cells; inactivation, or whatever. They have often recommend higher dose, pulse/intermittent therapy, in combination with other agents. Palbociclib is being looked at right now, because of its advancement in clinical trials, but I'm sure they will be ready for Bemaciclib when it becomes available.
One of those private laboratory oncologists, Dr. Robert A. Nagourney, will be attending the upcoming American Society of Clinical Oncology trade show in Chicago, where he will present early studies on Cyclin-dependent kinases as therapeutic targets: examination of palbociclib (PD0332991) and flavopiridol in human tumor primary culture microspheroids.
|
Threaded Mode